Our results showed that Mogamulizumab could effectively inhibit the local invasion and the metastasis of distant lymph nodes by blocking CCL2-CCR4-Vav2-Rac1-MLC signaling in the HNSCC xenograft model. This evidence concerns the gene RAC1 and head and neck squamous cell carcinoma.